comparemela.com

Latest Breaking News On - Prnewswire simcere pharmaceutical group - Page 1 : comparemela.com

First Prescription for COSELA® (trilaciclib) Issued in China

/PRNewswire/ Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics, Inc., (Nasdaq:.

United statesTang renhongJack baileySimcere pharmaceutical groupPrnewswire simcere pharmaceutical groupTherapeutics incResearch triangle parkNational comprehensive cancer networkChinese society of clinical oncologyJilin cancer hospitalPharmaceutical group limitedChief executive officerExecutive directorComprehensive cancerClinical practice guidelinesClinical oncology

Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237

/PRNewswire/ Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration.

United statesBijoyesh mookerjeePrnewswire simcere pharmaceutical groupSimcere pharmaceutical groupNational medical products administration onDrug administrationPharmaceutical groupNational medical products administrationChief medical officerPharmaceutical group limited

Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc

Simcere will receive a $15 million upfront payment, and up to $492 million in development and commercial milestone payments considering successful achievements.

Hong kongComunidad autonoma de catalunaRenhong tangKarl ziegelbauerPrnewswire simcere pharmaceutical groupSimcere pharmaceutical groupSpanish stock exchangeGreater chinaPharmaceutical groupMainland chinaChief scientificPharmaceutical group limitedNoble purposeSimcere pharmaceutical group limitedHealth care amp hospitalsMedical pharmaceuticals

Tamas Oravecz Ph D named SVP, CSO of the U S of Simcere Pharmaceutical Group

/PRNewswire/ Simcere Pharmaceutical Group announces today the appointment of Tamas Oravecz, Ph.D. as Senior Vice President, Chief Scientific Officer of the.

United statesTamas oraveczSimcere us tamasRenghong tangProgram headSimcere pharmaceutical groupDrug administrationUniversity of szeged hungaryBritish council imperial cancer research fundResearch centerKey laboratory of translational medicineNational institutes of health us foodSwiss society for immunologyFogarty international center national institutes of healthPrnewswire simcere pharmaceutical groupHungarian academy of sciences

Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65 4% of Total Revenue

/PRNewswire/ Simcere Pharmaceutical Group Limited (2096.HK) announced its financial results for the first half of 2022. As of June 30, Simcere recorded.

United statesHong kongPrnewswire simcere pharmaceutical groupHong kong stock exchangeSimcere pharmaceutical groupSimcere pharmaceuticalInnovative drug developmentKey laboratory of translational medicinePharmaceutical group limitedDrug evaluationState key laboratoryTranslational medicinePharmaceutical groupSimcere pharmaceutical group limited

vimarsana © 2020. All Rights Reserved.